Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage ...

Researchers from the University of Alabama at Birmingham have identified a promising new combination therapy for metastatic ...

This, in turn, prompts the downregulation of cyclin D2 and the upregulation of the p27kip1 protein, eventually leading to cell cycle arrest at the G1 phase. In terms of angiogenesis, HGF stimulates ...

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

Happy birthday to the world's first ever mirrorless camera, which just turned 16 years old! But is it still usable in 2024?

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

The Illinois Racing Board has approved the acquisition of FanDuel Sportsbook and Horse Racing, the former Fairmount Park, by ...

Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...

The firm is testing azenosertib as a single agent and in combination with other drugs in various solid tumors and looking at response biomarkers.